Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT04547062
PHASE1
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
Sponsor: Nantes University Hospital
View on ClinicalTrials.gov
Summary
This is a phase 1 dose escalation study testing the addition of an anti-IL6 (tocilizumab) to standard induction chemotherapy for high-risk AML.
Official title: Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) With Poor Prognosis: TOCILAM"
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2020-12-29
Completion Date
2023-04-04
Last Updated
2026-09-14
Healthy Volunteers
No
Conditions
Interventions
DRUG
Tocilizumab
Administration of tocilizumab at day 8 of induction following a classical induction
Locations (1)
CHU of Nantes
Nantes, France